Akums Drugs & Pharmaceuticals Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 20,343,188 (74%) | — | ₹138,130 Cr |
| NII (HNI) | — | 4,068,637 (15%) | — | ₹27,626 Cr |
| Retail | — | 2,712,424 (10%) | — | ₹1,842 Cr |
| Employee | — | 243,902 (1%) | — | ₹166 Cr |
| Σ Total | — | 27,368,151 (100%) | — | ₹1,858,297 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 22 | ₹14,938 |
| Retail (Max) | 13 | 286 | ₹194,194 |
| S-HNI (Min) | 14 | 308 | ₹209,132 |
| B-HNI (Min) | 67 | 1,474 | ₹1,000,846 |
Financial Statements Amount In Crore
| Metric | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Revenue | 4,212 | 3,701 | 3,695 |
| Profit After Tax | 1 | 98 | -251 |
| Net Worth | 710 | 717 | 622 |
| Total Assets | 3,516 | 3,267 | 3,069 |
| Reserves & Surplus | 861 | 869 | 788 |
| Total Borrowing | 492 | 537 | 358 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Repayment/ prepayment of indebtedness of the company and its Subsidiaries; –
- Funding incremental working capital requirements of the company; –
- Pursuing inorganic growth initiatives through acquisitions; and –
- General corporate purposes. –
Company Overview
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.